Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise nearly 28% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $35.16 to $36.15 since Mar 24, 2014.
The company has seen two negative estimate revisions in the past 30 days, while its Zacks Consensus Estimate moved lower over the same time frame, suggesting trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Agios Pharmaceuticals currently has a Zacks Rank #5 (Strong Sell) while its Earnings ESP is 0.00%.
Some better-ranked medical stocks that are worth considering include Enzymotec Ltd. (ENZY) and Covidien plc (COV). While Enzymotec sports a Zacks Rank #1 (Strong Buy), Covidien has a Zacks Rank #2 (Buy). Another stock worth considering in the broader healthcare industry is Alkermes plc (ALKS) with the same Zacks Rank as Enzymotec.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment